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Background: The prevalence and socioeconomic cost of late life depression (LLD) is on the rise, while the response
rate to antidepressant trials remains poor. Various mind-body therapies are being embraced by patients as they are
considered safe and potentially effective, yet little is known regarding the effectiveness of such therapies to improve
LLD symptoms. Among the mind-body therapies currently in practice, the results of our pilot study have shown that
a particular meditation technique called Sahaj Samadhi Meditation, which belongs to the category of meditation
termed automatic self-transcending meditation (ASTM) may have some promise in improving cardiovascular
autonomic disturbances associated with LLD as well as ameliorating symptoms of depression and anxiety.
Methods/Design: Patients between the ages of 60 and 85 with LLD will be randomized either to ASTM plus
treatment as usual (TAU) or TAU alone to assess changes in cardiovascular autonomic parameters,
neuropsychological symptoms of depression and anxiety as well as quality of life. The instructional phase of the
intervention consists of 4 consecutive days of meditation training, after which participants are encouraged to
meditate twice daily for twenty minutes each time at home. The intervention also includes once weekly follow up
sessions for the subsequent 11 weeks. The planned study has one and a half year recruitment period. Participants
will be assessed at baseline and at 4, 8, 12 and 24 weeks post intervention.
Discussion: This study should provide a unique data source from a randomized, controlled, longitudinal trial to
investigate the effects of a form of ASTM on cardiovascular autonomic and neuropsychological health in LLD.
Trial registration: Clinicaltrials.gov NCT02149810, date registered: 05/28/2014.
Keywords: Cardiovascular autonomic testing, Automatic self transcending meditation, Late life depression, Heart
rate variabilityBackground
Major depressive disorder in the elderly (above 60 years
of age), also known as late life depression (LLD), is a com-
mon disabling condition that is associated with a high
mortality rate, caused by either suicide or cardiovascular
events [1], thus compelling appropriate treatment.* Correspondence: akshya.vasudev@uwo.ca
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unless otherwise stated.Depression in general, and LLD in particular, is
increasingly recognized as a dysfunction in multiple
underlying biological processes with an increased pre-
valence of comorbid cardiovascular autonomic distur-
bances compared to age-matched controls [2,3], as
reported by us previously [4]. Other studies conducted
on depression across the human life span have re-
ported similar results [5,6], suggesting there may be an
etiological link between autonomic dysfunction and
LLD. This potential relationship necessitates further
evaluation as it could provide invaluable insight intotd. This is an Open Access article distributed under the terms of the Creative
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ment strategies.
Evidence shows that in a naturalistic setting, the re-
sponse rate to an antidepressant trial of adequate dose
and duration is often inadequate and can be as low as
30-40% in LLD [7]. In addition, antidepressant use is
often associated with a number of adverse events which
lead to frequent discontinuation of such treatment [8].
Hence there remains the need for additional safe and ef-
fective interventions [2].
Recently, various forms of non-pharmacological ther-
apies loosely defined as mind-body therapies such as
biofeedback, energy healing, meditation, guided im-
agery, and yoga [2,9] are being increasingly embraced by
patients. Such therapies have negligible side effects, are
easy to administer and display beneficial effects on quality
of life as well as comorbid anxiety. Unlike antidepressants
that classically alter neurotransmitter levels [3], mind-
body therapies target multiple organ systems and offer an
added advantage over anti-depressant treatment alone
by ameliorating both depression and cardiovascular
health when offered in combination with antidepres-
sants therapy.
Various forms of meditation have been employed as
mind-body treatments. Automatic self-transcending medi-
tation (ASTM) is a category of meditation that helps quiet
the mind and induce physiological and mental relaxation
while the eyes are shut. It utilizes relaxed attention to a
specific sound value (mantra) according to specific cri-
teria, in order to draw attention inward. This permits the
mind to experience a restful but alert state of conscious-
ness [10,11]. ASTM specifically improves autonomic
dysfunction among elderly with and without cardiovas-
cular disease and has a positive impact on depressive
symptoms and stress [12]. In a randomized controlled
trial of elderly retirement home residents comparing
ASTM with two other meditative techniques and treat-
ment as usual (TAU), ASTM produced significantly
greater improvements in cognitive function, cardiovascu-
lar function and quality of life than all other treatment
conditions [12,13]. Studies of ASTM in adults with cardio-
vascular disease further demonstrated improvements in
cardiovascular function including heart rate variability
(HRV) [13-16], an easily measurable cardiovascular auto-
nomic variable. A subsequent meta-analysis of all-cause
mortality rates among hypertensive elderly who had
participated in stress reduction interventions found that
ASTM practitioners had a 30% lower cardiovascular
mortality rate than four other meditative or relaxation
interventions [17].
These studies suggest that ASTM may be particularly
well suited to elderly populations. However, it has not
yet been shown if the benefits offered by ASTM would
translate to elderly depressed subjects. We found througha pilot study that ASTM led to an improvement in HRV
and was associated with reductions in symptoms of both
depression and anxiety. The data also showed that the
ASTM intervention did not induce any form of distress in
participants, adding to the utility of this practice as a
therapeutic tool. However, given that this was a pilot
study, further investigation is required. Therefore we aim
to assess ASTM in a large-sample randomized, controlled,
longitudinal trial to confirm its effectiveness. In this paper,
we provide a description of the protocol, participants’ in-
clusion/exclusion criteria, as well as cardiovascular and




The primary aim of this study is to examine whether or
not Sahaj Samadhi Meditation, a form of ASTM leads
to increased HRV in patients with LLD. Additional aims
are to examine its impact on symptoms of depression
and anxiety and to determine if it leads to improvements
in quality of life.
Study design
The study aims will be addressed via a single-centre,
single-blind, longitudinal randomized controlled natural-
istic trial.
Recruitment
Participants will be recruited from primary, secondary,
and tertiary care centers in London, Ontario. We expect
to recruit an average of two participants per week in a
staggered manner, over a one and a half-year period. A
telephone line will be available for study contact, concerns,
and queries. The study will be advertised at key areas
around the city including various community centers and
libraries, as well as via electronic, print and web media.
Participants
Research participants will be 96 elderly men and women,
who have mild to moderate major depressive disorder
(MDD). Diagnosis of MDD will be confirmed through a
Structured Clinical Interview for DSM-IV-TR (SCID)
Axis I disorder [18].
Eligibility assessment
Potential participants will be screened as per inclusion
and exclusion criteria at the Geriatric Mental Health
Program at London Health Science Center, London,
Ontario. The Program includes two geriatric psychiatrists,
registered nurses, and social workers, and serves adults
over 65 from London and Middlesex County [19]. The
Program accepts referrals from family physicians and
other healthcare providers. In order to meet the inclusion
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age, have a diagnosis of mild to moderate MDD with a 17
item Hamilton Depression Rating Scale (HAMD-17) score
of 8 to 22 [20], be of good general physical health, have
sufficient hearing to be able to follow verbal instruc-
tions, be able to sit without physical discomfort for
45 minutes and be able to attend 4 initial ASTM train-
ing sessions. They must also agree to home practice of
ASTM, and to attend 75% of weekly follow-up sessions.
If being treated with antidepressant medications, they
should be at therapeutic doses for a minimum of four
weeks. Exclusion criteria include participation in other
similar studies, other significant mental health diagno-
ses (including dementia, substance dependence, post
traumatic stress disorder, obsessive compulsive disorder,
bipolar disorder, neurocognitive disorder and personal-
ity disorders), high risk of suicide as elicited by clinical
interview, psychotic episodes within the past 12 months,
head trauma within the past 6 months, use of tricyclic
antidepressants, monoamine oxidase (MAO) inhibitors,
serotonin noradrenaline reuptake inhibitors (SNRI) or
antipsychotic agents, practice of any type of formal
meditation, mindfulness or breathing techniques, severe
cardiovascular disease (myocardial infarction, stroke or
transient ischemic attack) in the past 12 months, or any
history of neurological disease (including Parkinson’s
disease), seizures, or diabetic neuropathy.Baseline assessments
Once written consent is obtained from a potential par-
ticipant, a baseline assessment will be conducted to as-
certain the participant’s eligibility. Upon selection, each
participant will undergo a structured clinical interview;
SCID. The neuropsychological assessment consists of
four examiner-rated questionnaires including the Cu-
mulative Illness Rating Scale for Geriatrics (CIRS-G)
[21], Hamilton Depression Rating Scale (HAMD-17)
[20], Physical Activity Scale for the Elderly (PASE) [22],
and Mini Mental State Examination (MMSE [23]). Four
self-rated questionnaires will also be used to obtain
self-reports of depression, anxiety, quality of life, and
antidepressant side effects. These include the Geriatric
Depression Scale (GDS) [24], Geriatric Anxiety Inven-
tory (GAI) [25], Quality of Life Profile: Seniors Version
(QOLPSV) [26], and Toronto Side Effects Scale (TSES)
[27], respectively.Structured Clinical Interview for DSM-IV-TR Axis I Disorders
(SCID)
The SCID-I is a semi-structured interview for diagnos-
ing current and past DSM-IV Axis I disorders and has
excellent face and internal validity for diagnosing major
depression [18].Hamilton Depression Rating Scale (HAMD)
The HAMD is a 17-item structured scale administered
to individuals diagnosed with unipolar major depression.
It has been devised to quantify the severity of the de-
pressive symptoms of the patient, based on the necessary
information elicited by the interviewer [20]. It has been
used in innumerable clinical trials for monitoring the
change in mood state over a period of time.
Physical Activity Scale for the Elderly (PASE)
The PASE is a ten-item questionnaire assessing the fre-
quency and intensity of engagement in physical activities,
for individuals aged 65 and older, including walking,
housework, sports, and other recreational activities over a
one-week period [22].
Mini Mental State Examination (MMSE)
The MMSE is a quick test for grading the cognitive func-
tion or decline. Consisting of 11 questions and requiring
less than ten minutes to complete, it can be used to screen
for mild cognitive impairment or dementia [23].
Geriatric Depression Scale (GDS)
The 15-item GDS is a shortened version of the original,
30-item GDS questionnaire used to rate depression in
the elderly [24]. The 15-item version has been shown to
be effective in screening for depression in cognitively in-
tact older adults [28].
Geriatric Anxiety Inventory (GAI)
The GAI is a 20-item questionnaire used to detect the
presence of anxiety symptoms in older adults with or
without a comorbid diagnosis of Generalized Anxiety
Disorder (GAD). It has been found to be psychometric-
ally sound and effective at detecting either the presence
of GAD (using a cut off point of 8/9) or any anxiety dis-
order (using a cut point of 10/11) [25].
Clinical Global Impression-Improvement (CGI-I)
The CGI provides a summary of changes in an individual’s
clinical status from the previous assessment and uses a
seven-step categorical scale from 1 (very much improved)
to 7 (very much worse) [29].
Quality of Life Profile: Seniors Version (QOLPSV)
The QOLPSV (short) is a 54-item questionnaire asses-
sing quality of life in older adults using a model which
focuses on more than just the absence of disease. The
questionnaire aims to measure the “degree to which a
person enjoys the important possibilities of his/her life”
in the domains of Being (covering physical, psychological,
and spiritual wellness), Belonging (evaluating a person’s fit
in their social and physical environment), and Becoming
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aspirations) [26].Toronto Side Effects Scale (TSES)
The TSES is a comprehensive, 32-item score sheet asses-
sing the frequency and severity of various side effects
which may occur with antidepressant therapy. It pro-
vides information for the cost/benefit analysis of a treat-
ment since antidepressant medications tend to vary
based on their side-effect profiles more than their remis-
sion rates [27].Baseline demographic values
Baseline demographic values, which could act as covari-
ates or confounds for the tested treatment modality, will
be also collected. These include medication use (includ-
ing over the counter medication), number of previous
depressive episodes, age at onset of first depressive epi-
sode, body mass index (BMI), smoking behavior, alcohol
and coffee intake.Medication adherence
During the study period, specific antidepressants in-
cluding Selective Serotonin Reuptake Inhibitors (SSRIs),
(such as, fluoxetine, fluvoxamine, paroxetine, citalopram,
escitalopram, paroxetine), Noradrenergic and Specific Sero-
tonergic Antidepressants (NaSSAs) (such as, mirtazapine),
bupropion, and anxiolytics (such as, benzodiazepines,
zopiclone and trazodone) will be allowed as they have
been found to be safe on autonomic variables [30]. Dos-
ages will be optimized for a period of at least 4 weeks
prior to enrollment and dosage modifications will also
be permitted and monitored by pill count and history at
follow-up appointments.Randomization and blinding
After baseline assessments, participants will be random-
ized in blocks of four to ASTM+TAU or TAU equally
(1:1) using an online random allocation software v2.0
[31]. Concealment of randomization will be ensured by
an administrative staff member keeping the randomization
list in a locked cabinet inaccessible to other research staff.
Immediately after each randomization, the participants will
be notified of treatment allocation. Block randomization
will allow ASTM treatments to be conducted in groups of
four participants, minimizing therapist time while offering
the potential benefits of group therapy. Pre-randomized
information will be stored using unique identifiers on a
secure database. Outcome assessors will be blinded to
treatment. It will not be possible to blind participants to
intervention status.Interventions
ASTM treatment arm
Following the initial HRV and neuropsychological mea-
surements, participants in the ASTM arm will undergo
Sahaj Samadhi Meditation training in groups of four by
certified Sahaj Samadhi Meditation teachers under the
supervision of one of the study authors (RN). This in-
volves participating in 120-minute sessions on each of
four consecutive days. Participants will individually be
given a mantra on day one, and then be instructed in use
of the mantra according to specific criteria over the four
session program in groups of four. The training will
be done in a quiet room within the hospital. This will be
followed by weekly 60-minute follow up sessions for
the 11 subsequent weeks. In addition, participants will
be asked to practice ASTM at home for 20 minutes
twice daily over the study period (24 weeks) and to log
practice frequency and other noteworthy observations
in the log sheet provided to them.
TAU control arm
The control group will continue to receive treatment as
usual (TAU) including antidepressant medications and/
or psychotherapy. After week 12, TAU arm participants
will be offered the opportunity to learn ASTM and at-
tend follow up meditation sessions. However, no assess-
ments will be done or information collected on the TAU




These involve cardiovascular autonomic assessments
through electrocardiogram (ECG) and blood pressure
measurements along with the measurement of respiratory
excursions. These will be taken prior to the intervention
(baseline or week 0), 12 and 24 weeks post-intervention
for both ASTM and TAU groups. Participants from both
arms will be asked to report to the Laboratory for Brain
and Heart Health, Labatt Health Sciences Building, on the
Western University campus. Heart rate will be monitored
using an ECG with two adhesive leads or surface elec-
trodes placed on the chest and one on the abdomen.
Blood pressure will be measured using two small cuffs
placed on a finger and wrist (Finometer) and an arm cuff
device. The finger cuff continuous measures of blood
pressure will be confirmed against arm cuff values ob-
tained periodically by an automated sphygmomanometer
(Dinamap). A respitrace bellows placed around the abdo-
men will provide information on respiratory excursions.
Secondary outcomes
Depression and comorbid anxiety symptoms will be
assessed via the administered and self-rated scales (i.e.
Figure 1 Participant flow chart.
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GAI) at baseline (week 0) and 4, 8, 12 and 24 weeks post-
intervention. Physical activity, antidepressant side effects
and quality of life will also be assessed at the same time
using the PASE, TSES and QOLPSV, respectively. Anti-
depressant medication adherence threshold will be set
at 80% of pills consumed. Table 1 shows the primary
and secondary outcome measures for all participants from
weeks 0 to 24.
Patient adherence to the treatment
The research staff will record the number and duration of
all attended ASTM sessions, compliance to home practice
and the number of missed sessions. Based on this infor-
mation, we will calculate the proportion of missed sessions
as a quantitative index of treatment adherence.
Statistical analysis
The design for this investigation is a split-plot partial
hierarchical factorial design analysis of variance with twoprimary treatment conditions (ASTM+TAU vs TAU)
tested at fixed time intervals.
Sample size
The primary focus of this study is the interaction effect of
treatment on HRV. On the assumption that this effect size
is medium (Cohen’s f = 0.25), calculations (using G*Power)
[32] indicate that a sample size of 80 (4 in each of 20
groups) yield power estimates of 0.99 for both the inter-
action and the main effect of time. We intend to test a
total of 96 participants to cover a conservative estimate of
20% loss to follow up. Based on the data obtained from
the pilot study we consider these figures to be feasible.
Treatment effect
The power estimate for relevant simple main effects of
time for the ASTM treatment condition is 0.93 (or 0.83
Bonferroni once adjusted). Simple main effects of treat-
ment at each level of time are not expected for early
time periods, but could be present at 24 weeks with a
significant linear by linear interaction of time and treat-
ment. This contrast is estimated to have a power of 0.72
assuming a medium effect, but the effect might well be
stronger with the cumulative effects of time.
Primary outcomes
An upward deflection in an ECG is referred to as R wave
and R-R is the interval between successive Rs. The HRV
will be calculated by the standard deviation of all normal
R-R intervals (SDNN) on the ECG, the root-mean square
of successive differences (RMSSD), as well as the number
of R-R intervals differing by >50 milliseconds from adja-
cent intervals (NN50) according to time-domain analysis
that are based on beat-to-beat or NN intervals. Time-
domain analysis will be preferred over spectral density
analysis as it treats the NN interval sequence as an un-
ordered pairs of intervals [33], whereas spectral density
analysis presents information on the power distribution
(variance) of the ordered NN intervals across frequen-
cies [34].
Secondary outcomes
All secondary variables measured at the five time points
will be analyzed with a similar design (i.e. a 2×5 split plot
factorial design analysis of variance with groups crossed
with time but nested in treatment intervention). With the
total sample size of 80, this yields power estimates of
0.999 for both time and the treatment x time interaction.
Fidelity/confidentiality
All outcome data will be stored on a encrypted database
located on a secure server housed at the London Health
Sciences Centre.




Week 0 Week 1 Week 4 Week 8 Week 12 Week 24
Assessment of eligibility ✓
Informed Consent ✓
Heart rate variability, Blood pressure, Respiratory excursion ✓ ✓ ✓
To be completed by examiner: ✓
SCID
Suicide risk assessment ✓ ✓ ✓ ✓ ✓
Concomitant medication adherence record ✓ ✓ ✓ ✓ ✓
CIRS-G ✓
HAMD ✓ ✓ ✓ ✓ ✓
PASE ✓ ✓ ✓ ✓ ✓
CGI ✓ ✓ ✓ ✓
MMSE ✓
To be completed by participant: ✓ ✓ ✓ ✓ ✓
GDS
GAI ✓ ✓ ✓ ✓ ✓
QOLPSV ✓ ✓ ✓ ✓ ✓
TSES ✓ ✓ ✓ ✓ ✓
List of abbreviations:
HAMD-17: 17 item Hamilton Depression Rating Scale, CGI: Clinical Global Impression, GDS: Geriatric Depression Scale, GAI: Geriatric Anxiety Inventory, MMSE: Mini
Mental State Examination, PASE: Physical Activity Scale for the Elderly, CIRS-G: Clinician Illness Rating Scale-Geriatric version, QOLPSV: Quality of Life Profile:
Seniors Version.
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Effort will be made to promote participant retention by
allowing flexibility of screening and follow-up assessment
times, offering the meditation course at no cost, and offer-
ing monetary compensation for participant time.
Training of research staff
Research staff will receive training in the administration
of relevant scales by AV. The CIRS-G will be conducted
by one of the psychiatrists on the study team. All re-
search staff will also be trained on the SCID [18] using
the proprietary manual and instructional videos.
Ethics and safety
Ethical approval has been obtained from the University
of Western Ontario Health Sciences Research Ethics
Board (UWO HSREB#103966).
Risk screening
At both the baseline assessment and during frequent
follow-up interviews, any concerns of acute distress and
active suicidality/self-harm will be assessed by the psy-
chiatrists on the team. Individual patients will be with-
drawn from the study if there is reason to believe that
continuation with the program would be deleterious for
their mental health or safety. Particularly, participantinvolvement will be terminated if there are notable
increases in the total HAMD score and/or suicidal idea-
tion. In case of imminent risk, the patients will be re-
ferred to the Centralized Emergency Psychiatry Service
at London Health Sciences Centre. All scientific instru-
ments and the therapeutic modality have been previ-
ously shown to cause minimal to no discomfort. All sites
have access to first aid and cardiopulmonary resuscita-
tion in the event of an emergency. Participants will also
be asked to indicate any discomfort, at which time the
appropriate adjustments will be made, including discon-
tinuation of the experiment for that participant if neces-
sary. While participants are practicing ASTM techniques
at their own homes, there are no additional perceived
risks to their physical or mental health. As per the inclu-
sion criteria, only patients at low risk for suicide will be
recruited into the study.
Discussion
This paper describes the protocol of an innovative and,
to the best of our knowledge, the first randomized con-
trolled longitudinal trial that aims to examine the effi-
cacy of a non-pharmacological mind-body intervention
(ASTM) to improve cardiovascular autonomic function,
quality of life, and symptoms of depression and anxiety
in an older adult population suffering from depression.
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Recruitment has commenced and it is aimed to be com-
pleted by December 2015. Methods have been put in
place to ensure participants recruitment as per proto-
col. An extensive recruitment strategy has been devised
to engage primary care practitioners and general public
through radio talk shows, web, print and electronic
advertisements.
Autonomic disturbance has been reported in patients
with late life depression [2,3]. The primary outcome
measure assessing cardiovascular health (HRV) is a well-
established autonomic measure that has been used in
other trials [13-16]. It can be conveniently and quickly
collected. To collect the primary outcome measures col-
laboration has been set up with a neurovascular research
laboratory at Western University.
The secondary outcome measures (HAMD, PASE,
GDS, GAI, QOLPS, and TSES) will yield information on
expected improvements in depression, physical activity,
anxiety and quality of life. We shall be able to monitor
any side effects due to antidepressant use and to feed
this back to the participants for further discussion with
their treatment provider, if needed.
There is currently limited evidence regarding the effect-
iveness of mind-body therapies in the elderly population.
We have designed a robust randomized controlled trial
which would allow us to confirm if one such mind-body
therapy, ASTM improves cardiovascular autonomic imbal-
ance and improves severity of depression and quality of life.
Heart rate variability can be seen as a manifestation of
the interplay of the central nervous system and the auto-
nomic nervous system on a beat-by-beat basis [35]. If
there are positive effects of ASTM on HRV, then this form
of meditation could potentially improve cardiovascular
outcomes including myocardial infarction as well as mor-
tality in patients with LLD. Patients with depression at the
tested age range (60-85 years) usually develop a number of
comorbidities, such as hypertension and diabetes mellitus,
and often have a history of cardiovascular and cerebrovas-
cular events for which they require appropriate medica-
tions (e.g. beta blockers, calcium channel blockers, and
antiarrhythmics) which could influence the autonomic
variables being measured. Hence, it would be impossible
to completely exclude patients either with a history of car-
diovascular episode or currently on cardiovascular medi-
cations that might affect the primary outcomes of our
study. However, the randomization procedure will enable
us to control these variables by placing the participants in
one of the two treatment arms (ASTM+TAU and TAU
alone) with equal likelihood, which will also make the
findings of this naturalistic study more applicable to the
population seen in the clinic routinely.
This study is a practitioner-administered program. Such
programs tend to have higher rates of adherence andengagement than self-practice programs [36]. Based on
the evidence from previous studies conducted by one of
the co-investigators (RN), we have found that older adults
without depression have a very low attrition rate when
subject to ASTM [12]. The authors expect that the com-
bination of participant observation of improvements in
their psychological and physical health, as well as the
steps (described above) taken to make study assess-
ments non-cumbersome will help to maintain the reten-
tion rate of participants.
The ASTM program is highly transferable to other
practitioners through training and is easy to implement
in routine clinical care. As much of the cost of such an
intervention is associated with the development and ini-
tial testing, once evaluated it has the potential to be
adapted and rolled out with ease at relatively little cost
to a large number of elderly. We suspect that ASTM can
make LLD treatment cost effective by reducing both dir-
ect (i.e. hospitalization, physician visits, and medication)
and indirect medical costs (including home care by infor-
mal caregivers and loss of productivity by the caregiver).
This would be consistent with previous findings that
ASTM reduces medical care utilization [37] and costs
[38]. Although, there are no known direct risks of ASTM,
some reported adverse effects include relaxation-induced
anxiety, boredom, feeling addicted to the technique, and
mild dissociation. However, such effects have been found
mostly in individuals who practice meditative techniques
for several years; no other short-term adverse events have
been reported. Primary and secondary outcomes that will
be measured via minimally invasive tests have also shown
no direct risks. Prolonged use of finger and arm cuffs may
cause numbness and discoloration, which resolve upon re-
moval of the cuffs. ECG testing may cause some discom-
fort when electrodes are removed and the adhesive may
cause some redness on the skin that would dissipate
quickly at the end of the protocol.
Conclusion
It is proposed that ASTM augmentation is an effective
intervention that may ameliorate the autonomic disturb-
ance associated with LLD, reduce symptoms of depression
and anxiety, and improve quality of life compared to TAU.
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